Related to TAP, Open University to Develop 3-D CNS Tissue Models for Research, Drug Testing

• Elan Makes $20M Investment in Proteostasis as Part of Drug Discovery Partnership for Neurodegenerative Diseases
  
• Evotec and PsychoGenics Ally to Offer Integrated CNS Drug Discovery Solutions
  
• AMS Biotechnology to Distribute Reinnervate's 3-D Cell Culture Scaffold
  
• Merck Serono Pays Affectis €2.4M Up Front in Deal for Neurodegenerative Disease
  
• Researchers Say Human Nasal Cavity Stem Cells Repair Brain Damage in Mice
  
• Servier Positions Itself to Take Over Full Rights to CNS Disease Drug in Development with Cortex
  
• GlycoRegImmune Partners with RxMD to Progress NK T Cell-Targeting Drugs
  
• UCB and Harvard Establish Research Alliance to Develop Antibody Therapeutics
  
• Ipsen Renews Salk Institute Partnership and Signs Cancer Research Collaboration with IGR
  
• Quest Diagnostics and Genomic Vision Team Up to Develop Research and Clinical Testing Services
  
• NeurOp Wins $3M from NIH to Progress NMDA Antagonist for Preventing Stroke
  
• Eye Movements in Mice Used to Evaluate CNS-Active Drug Efficacy, Receptor Interaction, Pharmacokinetics, and Toxicity
  
• Siena Biotech Selects Proteome Sciences as Preferred Biomarker Service Provider
  
• GE Healthcare Adds Upstream Bioprocessing Capabilities with Acquisition of PAA Laboratories
  
• Diamyd Shifts Development Focus from Diabetes to Pain and CNS Disorders
  
• AMRI Wins Five-Year $43M NIH Contract for Work Focused on CNS Diseases
  
• Muscular Dystrophy Association Makes $13.7M Available to 40 Research Programs
  
• Rhenovia and French Army Awarded €1.15M to Develop Neurotoxin Biosimulation Platform
  
• Merck Serono Opens Biomarker R&D Lab at Pharmaron’s Facility in Beijing
  
• Researchers Use C. elegans to Identify Genes Critical to Nerve Repair